Cure My Disease

Don't miss your cure!

 Log in / Sign up

Radioactive antibody targets rare childhood cancer

NCT ID NCT04022213

Disease control Sponsor: Memorial Sloan Kettering Cancer Center Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 21, 2026 · Last updated Jul 22, 2026 · Updated 1 time

Summary

This phase 2 trial tests a combination treatment for desmoplastic small round cell tumor (DSRCT), a rare cancer that often spreads in the abdomen. Participants receive a single dose of a radioactive antibody called 131I-omburtamab directly into the abdomen, followed by targeted radiation to the whole abdomen. The goal is to see if this approach can delay or prevent the cancer from coming back after surgery and chemotherapy.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
a radioactive antibody called 131I-omburtamab given through a catheter into the abdomen, plus external beam radiation
What this could lead to
If it works, this combination could help prevent or delay the return of this rare cancer after surgery and chemotherapy.
What could go wrong
This is a small, early-phase trial with only 31 participants, so results may not apply widely. The treatment involves radiation and may cause side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

31 people

The number who actually took part.

Started

Jul 2019

Expected to finish

Jul 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

1 year and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Have the diagnosis of DSRCT confirmed at MSKCC * Age \>1 year and able to cooperate with radiation safety restrictions during therapy period. * Prior to intraperitoneal catheter placement * At least 1 weeks must have elapsed since prior chemotherapy * At least 2 weeks must have elapsed since biologic therapy * Toxicities of prior therapy must have resolved to grade 1 or less or to the patient's baseline At the completion of surgery, patients must fulfill all of the additional following criteria: * Have no definitive radiological evidence of disease active in liver or outside the abdomen/pelvic OR have had GTR of this disease at the time of catheter placement Exclusion Criteria: * Prior progression of disease * Prior hypothermic intraperitoneal chemotherapy (HIPEC) * Cardiac, pulmonary, and neurologic toxicities are greater grade 1 per NCI CTCAE version 5 * Renal, gastrointestinal, and hepatic, toxicities are greater than grade 2 (per NCI CTCAE version 5) * History of allergy to mouse proteins * Patients with grade 4 hypersensitivity reaction to radiolabeled iodine

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Desmoplastic small round cell tumor are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

desmoplastic small round cell tumor peritoneal carcinoma peritoneum cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Desmoplastic small round cell tumor Peritoneal cancer Peritoneal carcinoma

Contacts and locations

Locations

  • Memorial Sloan Kettering Cancer Center

    New York, New York, 10065, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.